[go: up one dir, main page]

GR3024271T3 - Interleukin-4 receptors - Google Patents

Interleukin-4 receptors

Info

Publication number
GR3024271T3
GR3024271T3 GR970401920T GR970401920T GR3024271T3 GR 3024271 T3 GR3024271 T3 GR 3024271T3 GR 970401920 T GR970401920 T GR 970401920T GR 970401920 T GR970401920 T GR 970401920T GR 3024271 T3 GR3024271 T3 GR 3024271T3
Authority
GR
Greece
Prior art keywords
receptors
interleukin
mammalian
dnas
products
Prior art date
Application number
GR970401920T
Other languages
English (en)
Inventor
David J Cosman
Linda Park
Bruce Mosley
Patricia Beckmann
Carl J March
Rejean Idzerda
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of GR3024271T3 publication Critical patent/GR3024271T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR970401920T 1988-10-31 1997-07-30 Interleukin-4 receptors GR3024271T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26504788A 1988-10-31 1988-10-31
US31943889A 1989-03-02 1989-03-02
US32615689A 1989-03-20 1989-03-20
US37092489A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
GR3024271T3 true GR3024271T3 (en) 1997-10-31

Family

ID=27500837

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970401920T GR3024271T3 (en) 1988-10-31 1997-07-30 Interleukin-4 receptors

Country Status (14)

Country Link
US (10) US5840869A (el)
EP (1) EP0367566B1 (el)
JP (1) JP2744821B2 (el)
AT (1) ATE153068T1 (el)
AU (1) AU643427B2 (el)
DE (1) DE68928043T2 (el)
DK (1) DK175583B1 (el)
ES (1) ES2103706T3 (el)
FI (1) FI106044B (el)
GR (1) GR3024271T3 (el)
IE (1) IE61013B1 (el)
IL (1) IL91705A (el)
NZ (1) NZ231189A (el)
WO (1) WO1990005183A1 (el)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
EP0490975A1 (en) * 1989-09-07 1992-06-24 Schering Corporation Interleukin-4 receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5449515A (en) * 1989-11-21 1995-09-12 University Of Melbourne Anti-inflammatory compositions and methods
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
EP0615546A1 (en) * 1991-11-27 1994-09-21 Schering Corporation Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
EP0689451A4 (en) * 1993-03-19 1997-08-20 Immunex Corp PHARMACEUTICAL COMPOSITIONS COMPRISING A LIGAND COMPLEXED WITH A SOLUBLE RECEPTOR
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5591825A (en) * 1994-07-05 1997-01-07 Tularik, Inc. Interleukin 4 signal transducers
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7078494B1 (en) * 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US6605271B2 (en) * 1996-08-23 2003-08-12 Human Genome Sciences, Inc. T1 receptor-like ligand II and uses thereof
US6586210B1 (en) 1996-08-23 2003-07-01 Human Genome Sciences, Inc. Polynucleotides encoding T1 receptor like ligand II
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
ATE409225T1 (de) * 1997-10-29 2008-10-15 Genentech Inc Durch wnt-1 induzierbare gene
US6703488B1 (en) * 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
PT1105485E (pt) 1998-08-21 2006-11-30 Immunex Corp Dna e polipeptídeos de il-1 epsilon humana
EP1939297A1 (en) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
DE69933696T2 (de) 1998-12-14 2007-08-23 Genetics Institute, LLC, Cambridge Cytokinrezeptor-kette
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6693172B1 (en) 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
US6455290B1 (en) 1999-07-09 2002-09-24 Pharmacia Italia S.P.A. Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
WO2001004270A1 (en) * 1999-07-13 2001-01-18 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
WO2001031005A2 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
EP1240358A4 (en) * 1999-12-10 2005-10-19 Human Genome Sciences Inc T1 RECEPTOR SIMILAR LIGAND II AND ITS USE
CA2394015C (en) 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
EP1158058A1 (en) * 2000-05-19 2001-11-28 Centre National De La Recherche Scientifique Compositions and methods suitable for nucleic acid analyses
WO2001090326A2 (en) 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US7259244B2 (en) 2000-06-16 2007-08-21 Nerviano Medical Sciences S.R.L. Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US6896906B2 (en) 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
DK1434871T3 (en) * 2001-09-20 2017-04-18 Immunex Corp SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES
JP2005523681A (ja) 2001-10-04 2005-08-11 イミュネックス・コーポレーション Ｕｌ１６結合タンパク質４
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
MXPA04009381A (es) 2002-03-27 2005-01-25 Immunex Corp Metodos para incrementar la produccion de polipeptidos.
ATE353954T1 (de) * 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
AU2003303071B2 (en) 2002-12-16 2009-04-23 Technion Research & Development Foundation Ltd. Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same
AU2004207476A1 (en) * 2003-01-18 2004-08-12 Children's Hospital Medical Center Regulation of allergen induced gene
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA06000974A (es) 2003-07-25 2006-08-31 Amgen Inc Antagonistas y agonistas de ldcam y metodos para su uso.
MXPA06004853A (es) * 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CA2551110C (en) 2003-12-23 2016-01-19 Tanox, Inc. Treatment of cancer with novel anti-il 13 monoclonal antibodies
ATE395358T1 (de) 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
DE602005020755D1 (de) 2004-03-05 2010-06-02 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
US7319015B2 (en) 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
US7541158B2 (en) 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
PL1742658T3 (pl) 2004-04-23 2015-05-29 Zoetis Services Llc Czynnik permisywności komórkowej wobec wirusów i jego zastosowania
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US20080311078A1 (en) * 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
KR20070009269A (ko) 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
AU2006318580A1 (en) * 2005-11-21 2007-05-31 Merck Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US8101173B2 (en) * 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
US8206702B2 (en) * 2005-12-21 2012-06-26 Sentoclone International Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
WO2007071390A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
ATE520032T1 (de) 2006-06-21 2011-08-15 Apogenix Gmbh Differentielle cytokinexpression bei einer menschlichen krebserkrankung
EP2049147A2 (en) * 2006-07-06 2009-04-22 Apogenix GmbH Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008131376A2 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP3211010A1 (en) * 2007-12-21 2017-08-30 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
MX2010011955A (es) 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP2113261B1 (en) * 2008-04-29 2013-11-06 Proxy Biomedical Limited A Tissue Repair Implant
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CA2730050A1 (en) * 2008-07-18 2010-01-21 Sentoclone Ab Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
WO2010024927A2 (en) 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP2370470B1 (en) 2008-12-04 2016-10-05 Korea Research Institute of Bioscience and Biotechnology Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120076754A1 (en) 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2501398A1 (en) 2009-11-06 2012-09-26 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of atherosclerosis
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011089152A1 (en) 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
HUE044419T2 (hu) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Feldogozható egyetlen láncú molekulák és ezek alkalmazásával készült peptidek
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US20130195863A1 (en) 2010-09-28 2013-08-01 Philippe Clezardin Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
ES2668895T3 (es) 2011-03-16 2018-05-23 Amgen Inc. Variantes de Fc
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012152882A1 (en) 2011-05-10 2012-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune diseases
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2535714A1 (en) * 2011-06-16 2012-12-19 Istituto Nazionale Di Genetica Molecolare-INGM Biomarkers for autoimmune liver diseases and uses thereof
CA2952347A1 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EA201490555A1 (ru) 2011-09-02 2014-07-30 Эмджен Инк. Фармацевтический продукт и способ анализа реакции фармацевтического продукта на свет
MY173865A (en) 2011-09-22 2020-02-25 Amgen Inc Cd27l antigen binding proteins
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
JP6082402B2 (ja) 2011-11-28 2017-02-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 加齢に伴う機能障害の処置に使用するための薬学的組成物
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
JP6247226B2 (ja) 2012-01-10 2017-12-13 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 血液脳関門を越える治療分子の輸送の向上
KR102213694B1 (ko) 2012-04-27 2021-02-09 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
US9198949B2 (en) 2012-06-06 2015-12-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of cancer
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3
WO2014015148A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
BR112015003590A8 (pt) 2012-08-21 2017-10-31 Sanofi Sa Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2929024B1 (en) 2012-12-07 2019-05-29 North Carolina State University Beta-hexosyl-transferases and uses thereof
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US20140271629A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
ES2674697T5 (es) 2013-03-14 2022-04-19 Amgen Inc Eliminación de ligando de purificación por afinidad filtrado
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US9676851B2 (en) 2013-03-15 2017-06-13 Amgen Inc. Human PAC1 antibodies
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
ES2692657T3 (es) 2013-05-30 2018-12-04 Kiniksa Pharmaceuticals, Ltd. Proteínas de enlace al antígeno del receptor de oncastatina
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014284235B2 (en) 2013-06-21 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
MX2016002799A (es) 2013-09-13 2016-05-26 Genentech Inc Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
JP6621744B2 (ja) 2013-10-31 2019-12-18 アムジエン・インコーポレーテツド 組換えタンパク質のグリコシル化を調節するためのモネンシンの使用
WO2015086727A2 (en) 2013-12-11 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method for patients suffering of a cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EA202191909A1 (ru) 2014-01-13 2022-01-31 Эмджен Инк. Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
KR102519540B1 (ko) 2014-01-29 2023-04-10 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
JP6619745B2 (ja) 2014-02-20 2019-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
NO2785538T3 (el) * 2014-05-07 2018-08-04
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
EP4372078A3 (en) 2014-06-04 2024-09-04 Amgen Inc. Methods for harvesting mammalian cell cultures
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
ES2962593T3 (es) 2014-11-19 2024-03-20 Amgen Inc Cuantificación de resto glucano en glucoproteínas recombinantes
EA036178B1 (ru) 2014-12-01 2020-10-09 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе гликопротеинов
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MX2017010066A (es) 2015-02-04 2017-11-01 Hoffmann La Roche Oligomeros antisentido de tau y usos de los mismos.
JP6772156B2 (ja) 2015-02-04 2020-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 治療用分子を選択する方法
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
CA3232651A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20180237542A1 (en) 2015-09-15 2018-08-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
MX2018003445A (es) 2015-09-22 2018-08-01 Genentech Inc Expresion de proteinas que contienen fc.
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
KR102579850B1 (ko) 2016-07-22 2023-09-18 암젠 인크 Fc-함유 단백질의 정제 방법
EP3506931B1 (en) 2016-09-01 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
EP3538555A1 (en) 2016-11-14 2019-09-18 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN110770250B (zh) 2017-04-21 2025-01-07 伊兰科美国公司 用于兽医用途的il4/il13受体分子
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
PE20200013A1 (es) 2017-06-20 2020-01-06 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3658581A1 (en) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
LT3661562T (lt) 2017-08-04 2024-10-25 Amgen Inc. Cys-mab konjugavimo būdas
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
CN111954719A (zh) 2018-03-26 2020-11-17 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
IL278211B1 (en) 2018-05-01 2023-10-01 Amgen Inc Antibodies with modulated glycan profiles
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
US20210379146A1 (en) 2018-10-04 2021-12-09 Inserm (Institut National De La Santé Et De La Recherche Médigale) Method to restore or improve cognitive functions
WO2020074005A1 (en) * 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric genes
KR20210101270A (ko) 2018-12-10 2021-08-18 암젠 인크 돌연변이 피기백 트랜스포사제
JP2022526738A (ja) 2019-03-21 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アレルギーを治療するためのｉｌ－４／ｉｌ－１３経路阻害剤と形質細胞除去の組み合わせ
EA202193322A1 (ru) 2019-05-30 2022-03-10 Эмджен Инк. Конструирование шарнирной области для управления димеризацией антител
AU2020304671A1 (en) 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
US20220289807A1 (en) 2019-08-13 2022-09-15 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
JP2022549329A (ja) 2019-09-26 2022-11-24 アムジェン インコーポレイテッド 抗体組成物を製造する方法
EP4054590A1 (en) 2019-11-04 2022-09-14 Amgen Inc. Methods for treating leukemia
WO2021092355A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
EP4061838A1 (en) 2019-11-19 2022-09-28 Amgen Inc. Novel multispecific antibody format
KR20220114595A (ko) 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
KR20220117300A (ko) 2019-12-20 2022-08-23 암젠 인크 고형 종양의 치료를 위한 메소텔린-표적화 cd40 작용성 다중특이성 항체 작제물
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
CA3197047A1 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
US20240002545A1 (en) 2020-11-10 2024-01-04 Amgen Inc. Novel linkers of multispecific antigen binding domains
AU2022263406A1 (en) 2021-04-20 2023-10-19 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2022261299A1 (en) 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
MX2024003852A (es) 2021-10-05 2024-05-24 Amgen Inc Unión al receptor fc-gamma y contenido de glucanos.
AU2022424002A1 (en) 2021-12-29 2024-06-13 Bristol-Myers Squibb Company Generation of landing pad cell lines
EP4490178A1 (en) 2022-03-09 2025-01-15 Amgen Inc. Optimized transfection protocol
WO2023175022A1 (en) 2022-03-16 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat infectious diseases
EP4518839A2 (en) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
KR20250004863A (ko) 2022-05-02 2025-01-08 리제너론 파아마슈티컬스, 인크. 항-인터류킨-4 수용체(il-4r) 항체 제형
EP4406973A1 (en) 2023-01-27 2024-07-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025006529A1 (en) 2023-06-27 2025-01-02 Amgen Inc. Charge pair mutations to enable correct heavy-light chain pairing
WO2025024295A1 (en) 2023-07-21 2025-01-30 Amgen Inc. Vectors incorporating a combination of promoters driving selectable marker expression
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
ATE93144T1 (de) * 1988-02-02 1993-09-15 Schering Biotech Corp Methode zur verminderung der immunglobulin-ereaktion.
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
KR0172123B1 (ko) * 1989-03-07 1999-02-01 게르하르트 후버; 루돌프 호프만 재조합 단백질 수용체
EP0490975A1 (en) * 1989-09-07 1992-06-24 Schering Corporation Interleukin-4 receptors
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
EP0615546A1 (en) * 1991-11-27 1994-09-21 Schering Corporation Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
EP0689451A4 (en) * 1993-03-19 1997-08-20 Immunex Corp PHARMACEUTICAL COMPOSITIONS COMPRISING A LIGAND COMPLEXED WITH A SOLUBLE RECEPTOR

Also Published As

Publication number Publication date
US5840869A (en) 1998-11-24
US6391581B1 (en) 2002-05-21
DK78491D0 (da) 1991-04-29
US5856296A (en) 1999-01-05
US7317090B2 (en) 2008-01-08
EP0367566B1 (en) 1997-05-14
ES2103706T3 (es) 1997-10-01
AU4411389A (en) 1990-05-28
DK78491A (da) 1991-04-30
IL91705A0 (en) 1990-06-10
US20050118176A1 (en) 2005-06-02
AU643427B2 (en) 1993-11-18
DE68928043T2 (de) 1997-09-11
DK175583B1 (da) 2004-12-13
US5717072A (en) 1998-02-10
JP2744821B2 (ja) 1998-04-28
WO1990005183A1 (en) 1990-05-17
JPH02215385A (ja) 1990-08-28
US5599905A (en) 1997-02-04
FI106044B (fi) 2000-11-15
EP0367566A1 (en) 1990-05-09
ATE153068T1 (de) 1997-05-15
US20090226472A1 (en) 2009-09-10
US6548655B1 (en) 2003-04-15
IL91705A (en) 1998-12-27
DE68928043D1 (de) 1997-06-19
US5767065A (en) 1998-06-16
NZ231189A (en) 1991-06-25
IE893027L (en) 1990-04-30
FI912064A0 (fi) 1991-04-29
US20030185821A1 (en) 2003-10-02
IE61013B1 (en) 1994-09-07
US6716587B2 (en) 2004-04-06

Similar Documents

Publication Publication Date Title
GR3024271T3 (en) Interleukin-4 receptors
EP0318296A3 (en) Interleukin-1 receptors
IE902158L (en) Interleukin-7 Receptors
ZA887773B (en) Interleukin-7
GR3019333T3 (en) Tumor necrosis factor-alpha and -beta receptors
IL98205A0 (en) Type ii interleukin-1 receptors
AU2872089A (en) Receptor protein for human b cell stimulatory factor-2
AU6733487A (en) Mammalian interleukin-4
DE69633866D1 (en) Chemokin typ cc-ahnliches protein
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor